Evaluating SARS-CoV-2 IgG seroprevalence in the Okinawa islands of Japan

Okinawa Prefecture, Japan has experienced a total of six coronavirus disease 2019 (COVID-19) waves as of January 10, 2022. COVID-19 has been caused by the rapid spread of the severe acute respiratory syndrome coronavirus-2 (SAR-CoV-2).

Okinawa Prefecture contains a large number of remote islands centered around the Okinawa main island in a vast ocean area. In a recent study published on the preprint server medRxiv*, scientists reveal that the pattern of the pandemic may significantly differ between the main island and remote islands.

Study: SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021. Image Credit: MTX-design / Shutterstock.com

Study: SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021. Image Credit: MTX-design / Shutterstock.com

*Important notice: medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Background

Generally, medical resources in the remote islands are scarce, and, many times, patients are transferred from the island’s limited facility clinics to larger well-resourced islands by air or sea according to the patient's condition. As a result of these limited resources, a substantial number of patients who suffer mild to moderate SARS-CoV-2 infection go unreported.

According to a report, 20% of elderly persons can contract COVID-19 asymptomatically. Researchers further estimated that 6.4% of individuals who are above 70 years of age experience severe COVID-19.

Owing to a large number of unreported cases and the poor prognosis of a subset of patients, it is imperative to perform frequent serological surveys to have a better understanding of the disease dynamics caused by SARS-CoV-2.

Scientists have revealed that estimating the proportion of previously infected people is a useful indicator to determine the unreported cases that created biases in previous surveillance systems, the real incidence rate of severe disease, mortality, and extent of herd immunity. Although several seroepidemiological surveys had been conducted in Japan, they were limited to urban areas such as Tokyo, Miyagi, and Osaka, or a single hospital or private company.

Location of Okinawa Prefecture and six healthcare facilities participated in the study.

In addressing this limitation, the scientists of the current study conducted a seroepidemiological survey focusing on the rural population in Japan. Moreover, the scientists perform serological analysis against SARS-COV-2 infection in different island groups in Okinawa, which allowed them to subsequently determine the surge in COVID-19 cases over time through statistical methods.

About the study

The authors performed seroepidemiological surveys at three different periods between 2020 and 2021, which allowed them to estimate the proportion of previously infected people in Okinawa's main island and remote islands. Interestingly, scientists observed that the majority of the population in the Okinawa main island were not infected by COVID-19 as of February 2021, thereby indicating that large-scale transmission did not occur.

In addition, seroprevalence among the elderly over the age of 60 was found to be relatively low. Similar to many countries, the Japanese government also prioritized COVID-19 vaccination for health care workers, followed by the elderly.

During the study period, a majority of the local population, except healthcare workers, had not been vaccinated. Researchers observed that most of the survey participants were at a high risk of contracting SARS-CoV-2 infection; thus, they strongly supported the government policy of vaccinating the elderly group with priority.

The scientists estimated the seroprevalence of 0.0% in July 2020 in the Okinawa main island. Interestingly, this result was similar to the seroprevalence of 0.0% in Miyagi Prefecture in early June 2020, which experienced a low attack rate of 0.004% as of May 31, 2020.

However, the seroprevalence in Okinawa could be higher compared to Miyagi Prefecture during the first survey due to the SARS-CoV-2 transmission rate being 2.5 times higher in Okinawa Prefecture than in Miyagi Prefecture. Additionally, the participants associated with Okinawa’s serosurvey were mainly from the emergency outpatient department, while random sampling was conducted for Miyagi’s serosurvey.

Similar to previous studies conducted in other parts of Japan, the current study revealed prefectural-level case detection ratios ranging from 2.2 to 2.8. Comparatively, the current surveillance system effectively estimated the real number of SARS-CoV-2 incident cases in a much more efficient manner.

During the second survey, the spread of the epidemic remained limited; however, seroprevalence was higher in the older group as compared to the younger age group. The reports of the third survey indicated that SARS-CoV-2 had spread more widely and that the detection ratios of people between 20 and 29 years of age were much higher than those belonging to other age groups.

The characteristics of the distribution of the attack rate in the remote islands were similar to those of the main island, especially during the third survey, when the epidemic was spreading widely.

Limitations

The current study had some limitations which included a small sample size, owing to which, the uncertainty bounds were quite wide. Further, the estimation of a small number of younger people with COVID-19 could be due to bias, as tests were typically not conducted in younger people due to insufficient testing systems. The study cohort contained emergency outpatients, which might not be the true representation of the local population in terms of their risk of exposure to COVID-19.

*Important notice: medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
Dr. Priyom Bose

Written by

Dr. Priyom Bose

Priyom holds a Ph.D. in Plant Biology and Biotechnology from the University of Madras, India. She is an active researcher and an experienced science writer. Priyom has also co-authored several original research articles that have been published in reputed peer-reviewed journals. She is also an avid reader and an amateur photographer.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Bose, Priyom. (2022, March 07). Evaluating SARS-CoV-2 IgG seroprevalence in the Okinawa islands of Japan. News-Medical. Retrieved on November 23, 2024 from https://www.news-medical.net/news/20220307/Evaluating-SARS-CoV-2-IgG-seroprevalence-in-the-Okinawa-islands-of-Japan.aspx.

  • MLA

    Bose, Priyom. "Evaluating SARS-CoV-2 IgG seroprevalence in the Okinawa islands of Japan". News-Medical. 23 November 2024. <https://www.news-medical.net/news/20220307/Evaluating-SARS-CoV-2-IgG-seroprevalence-in-the-Okinawa-islands-of-Japan.aspx>.

  • Chicago

    Bose, Priyom. "Evaluating SARS-CoV-2 IgG seroprevalence in the Okinawa islands of Japan". News-Medical. https://www.news-medical.net/news/20220307/Evaluating-SARS-CoV-2-IgG-seroprevalence-in-the-Okinawa-islands-of-Japan.aspx. (accessed November 23, 2024).

  • Harvard

    Bose, Priyom. 2022. Evaluating SARS-CoV-2 IgG seroprevalence in the Okinawa islands of Japan. News-Medical, viewed 23 November 2024, https://www.news-medical.net/news/20220307/Evaluating-SARS-CoV-2-IgG-seroprevalence-in-the-Okinawa-islands-of-Japan.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Could vitamin D help COVID-19 patients? Meta-analysis highlights potential ICU reduction